From most indications, the industry is on the march again after a solid 2003, and the coming year promises even more excitement - which means more competition, especially in key therapeutic areas.

On the heels of positive early Phase I/II data for bleeding control during coronary artery bypass graft (CABG) surgery, Dyax Corp. said it has agreed to sell about 5.2 million shares for $7.93 each, raising about $41.4 million pursuant to a shelf registration. (BioWorld Today)